The global phosphoinositide 3-kinase inhibitor market is poised to witness significant growth, projected to expand at a robust CAGR of 5.61% during the forecast period from 2019 to 2026.

Q-901 is under clinical development by Qurient and currently in Phase II for Metastatic Pancreatic Cancer. According to GlobalData, Phase II drugs for Metastatic Pancreatic Cancer have a 31% phase ...

Highlights in chronic myeloid leukemia from ASH 2024 include data on efficacy of asciminib over TKIs, benefit from the third-generation TKI olverembatinib, and importance of molecular monitoring.

Fadraciclib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase II for Uterine Cancer.

By inhibiting the DNA polymerases, BKC enhances the endogenous RS in cancer cells, leading to increased DNA damage. IBC specifically inhibits CHK2 to prevent DNA repair. The combined use of BKC and ...

NX-5948 has received fast track designation for adults with relapsed or refractory Waldenström macroglobulinemia who received ...

Day One Biopharmaceuticals shows promise in pediatric glioma treatment with strong financial health and a promising drug ...

ORLANDO -- Major cardiovascular event risk in patients with inflammatory bowel disease (IBD) was no greater with Janus kinase ...

For both the SAD and MAD portions of the trial, pharmacodynamic markers, including pSTAT levels, were measured.

Deepinder Dhaliwal, MD, LAc, explores advancements in managing Fuchs endothelial corneal dystrophy, highlighting Descemet ...

Ivarmacitinib, a novel Janus kinase 1 inhibitor, may be considered a potential treatment for patients with moderate to severe ...